This medicine protocol is a specific written instruction for the administration of Menjugate (Meningococcal Group C conjugate vaccine) to refugees and applicants seeking protection in Ireland (hereafter referred to as vaccine recipients) and in the event of an outbreak by registered nurses and registered midwives. This medicine protocol is valid for the 2025/2026 Health Service Executive (HSE) Primary Childhood Immunisation Programme (PCIP), Schools Immunisation Programme (SIP) and for National Immunisation Advisory Committee (NIAC) recommended catch up vaccination programme, and in the event of an outbreak as advised by public health.

This medicine protocol enables registered nurses and registered midwives employed in the voluntary and statutory services of the HSE including HSE Community vaccination clinics who have undertaken the required education and training programmes to administer Menjugate (Meningococcal Group C conjugate vaccine) with reference to and guidance from Nursing & Midwifery Board of Ireland (NMBI), National Immunisation Advisory Committee (NIAC), National Immunisation Office (NIO), HSE and in accordance with the Summary of Product Characteristics (SmPC) for Menjugate (Meningococcal Group C conjugate vaccine)as detailed by the Health Products Regulatory Authority (HPRA) at www.hpra.ie

- An Bord Altranais (2007) Guidance to Nurses and Midwives on Medication Management. Dublin: An Bord Altranais
- National Immunisation Advisory Committee (2023) Anaphylaxis: Immediate Management in the Community available at: https://www.higa.ie/reports-and-publications/niac-immunisation-guideline/anaphylaxis
- National Immunisation Advisory Committee *Immunisation Guidelines for Ireland* available at: https://www.hiqa.ie/areas-we-work/national-immunisation-advisory-committee/immunisation-guidelines-ireland
- National Immunisation Office (2025) Children Who Have Come To Ireland From Another Country: Information
 For Healthcare Professionals On Catch-Up Vaccination available at
 https://www.hse.ie/eng/health/immunisation/hcpinfo/botpipa/hcwcatchupothercountries.pdf
- National Immunisation Office (2025/2026) *Supporting Information for Staff: Schools Immunisation Programme* available at: https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/supportingdoc-2025.pdf
- National Immunisation Office (2025) Supporting Information for Vaccinations in General Practice available at: https://www.hse.ie/eng/health/immunisation/infomaterials/gpsupportingdocpci.pdf
- Nursing and Midwifery Board of Ireland (2025) Code of Professional Conduct and Ethics for Registered
 Nurses and Registered Midwives incorporating the Scope of Practice and Professional Guidance. Dublin:
 Nursing and Midwifery Board of Ireland available at: https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Code-ofProfessional-Conduct-and-Ethics.pdf?ext=.pdf
- Nursing and Midwifery Board of Ireland (2020) Guidance for Registered Nurses and Registered Midwives on Medication Administration. Dublin: Nursing and Midwifery Board of Ireland available at: https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Medication-Administration-2020.pdf?ext=.pdf
- Nursing and Midwifery Board of Ireland (2022) Practice Standards for Midwives. Dublin: Nursing and
 Midwifery Board of Ireland available at: https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Practice-Standards-for-Midwives.pdf?

The Nursing and Midwifery Board of Ireland defines medicine protocols as "written directions that allow for the supply and administration of a named medicinal product by a registered nurse or midwife in identified clinical situations. A medication protocol involves the authorisation of the nurse or midwife to supply and administer a medication to groups of patients in a defined situation meeting specific criteria and who may not be individually identified before presentation for treatment (AnBord Altranais, 2007, page 37).

event of an outbreak				
Document reference number	Version4-NIO-MenC-November			
.0 Critical elements				
Name of Organisation /Setting where medicine protocol applies	Health Service Providers across the voluntary and statutory services of the HSE including HSE community vaccination clinics. This Medicine Protocol applies to: • registered nurses and registered midwives employed in the voluntary and statutory services of the HSE including HSE Community vaccination clinics, congregated settings, temporary clinics and mobile units			
Date the medicine protocol comes into effect	November 2025			
Date for review of medicine protocol	November 2026			
Document prepared by	National Immunisation Office (NIO) in collaboration with the Office of the Nursing and Midwifery Services Director (ONMSD) HSE.			
Names and Signatures of the employing authority who is authorising the implementation of the medicine protocol "On behalf of the	Name: Dr. Éamonn O 'Moore Director of National Health Protection			
authority employing professionals authorised to administer under this medicine protocol, I have read this medicine protocol and authorise its implementation"	Signature: Name: Dr Colm Henry , Chief Clinical Officer, HSE			
	Signature:			
	Name: Dr Geraldine Shaw , Nursing and Midwifery Services Director, HSE Signature:			

2.0 Clinical Criteria						
Clinical condition for use of the medicine protocol	The clinical condition for which this medicine protocol has been developed is for the active immunisation against and prevention of Meningococcal Group C (Men C) disease.					
Circumstances in which the medicine protocol applies	To provide a Menjugate (Meningococcal Group C conjugate vaccine to vaccine recipients and in the event of an outbreak as advised by Public Health.					
Inclusion criteria for	For primary immunisation					
vaccine recipients receiving Menjugate (Meningococcal Group C conjugate vaccine) under this medicine protocol	For children born on or before the 30 th September 2024 the primary schedule consists of 2 doses with the first being administered at 6 months of age and a second dose of Hib/MenC at 13 months of age.					
	For children born on or after the 1st October 2024 the primary schedule consists of 1 dose at 13 months of age					
	For catch up program	mme				
	Unvaccinated children		ears of age should be	vaccinated as per the		
	Age	4 months to <12 months	1 to < 2 years	2-<4 years		
		If born on or before the 30 th September 2024				
	*MenC Vaccine	1 dose	1 dose	1 dose		
			1			
	Age	4 -9 years	10 -17 years	18 years and older		
	*MenC Vaccine	1 dose	1 dose up to 23 years of age, if Men C containing vaccine not given at age >10years	1 dose up to 23 years of age, if Men C containing vaccine not given at age ≥10years		
	For outbreak response: As advised by public health					
	For outbreak respon	se: As advised by pul	olic health			
	Precaution	febrile illness, defer un e of a minor infection s er is not a contraindica	ntil recovery such as a mild upper re ation to immunisation.	espiratory infection or		
	Precaution	febrile illness, defer un e of a minor infection s er is not a contraindica ccines (except for CO	ntil recovery such as a mild upper re ation to immunisation. VID-19 vaccine given to	espiratory infection or		
	Precaution	febrile illness, defer une of a minor infection ser is not a contraindicate ccines (except for CO) ears where a 14-day instered at the same time can be given on the	ntil recovery such as a mild upper reation to immunisation. VID-19 vaccine given to the successive of	espiratory infection or to children aged 6 ed) and other vaccines erval before or after		

Exclusion criteria for vaccine recipients receiving Menjugate (Meningococcal Group C conjugate vaccine) under this medicine protocol	Previous anaphylactic react	ion to any of the vaccine const	tituents.
Actions to be taken for those who are excluded from the medicine protocol Description of circumstances and	an individual assessment. Document action in Where Menjugate (following clinical as Menjugate (Mening practice. Note: In determining their so judgements about their com	Meningococcal Group C conju sessment, the registered nurse ococcal Group C conjugate va	gate vaccine) is prescribed e or midwife may administer accine) within their scope of the rses and midwives must make activity (NMBI, 2025).
referral arrangements when further advice or consultation is required	Other clinical conce	rns	
Documentation required to support implementation of the medicine protocol 3.0 Name of medicine	children who receive the Me Children aged 16 years and translation of consent is und details including the batch in The following documents wi Vaccination session Blank vaccine conse Vaccine Information Patient held record Post vaccination ad It is the responsibility of eac appropriate documentation (Meningococcal Group C co This medicine proto NIAC (2023) Anaph	ent forms Leaflets cards/ vaccine passport vice should be provided h registered nurse or midwife to support the safe administrationjugate vaccine) which include col col cylaxis: Immediate Managementie/reports-and-publications/nictis ns suspension for injection njugate vaccine	the Vaccine (Menjugate). In alf, once understood and lator if required. Appropriate the consent form. It is be familiar with the lion of Menjugate less the following: In the Community available
	Patients Age	Site	Needle length & Size
	Birth to <12 months	Vastus lateralis muscle	25 mm (Use a 16 mm needle in infants under 2.5 - 3 kg)
			23-25 gauge
	12 to <36 months	Vastus lateralis or deltoid muscle (depending on muscle mass)	25 mm 23-25 gauge
	3 years and older	Deltoid muscle	25 mm
			23-25 gauge

event of an outbreak					
Link to Medicine	Link to Summary of Product Characteristics:				
Details of product	https://assets.hpra.ie/products/Human/22980/Licence PA0919-004-				
information and other	<u>003_05112021142113.pdf</u>				
data including	Link to Dations Information Localists				
instructions for supply	Link to Patient Information Leaflet: https://assets.hpra.ie/products/Human/22980/pil-2195718-29012018151204-				
and administration is	636528355258437500.pdf				
available from the HPRA	<u>.0000200407000.pui</u>				
at <u>www.hpra.ie</u>					
Due and desired from the second from					
Procedure for reporting and documentation of	In the case of medicine errors that directly involve the vaccine recipient, i.e. wrong				
errors and near misses	medicine/patient/dose/route being administered or another medicine error, the registered				
involving the vaccine	nurse or registered midwife must remain with the vaccine recipient and closely monitor				
intermig and russing	them for any adverse reactions.				
	Vital signs should be recorded and the vaccine recipient should be reviewed by the				
	Vital signs should be recorded and the vaccine recipient should be reviewed by the				
	registered nurse/midwife and/or medical practitioner.				
	The incident must be reported to the relevant line manager as soon as possible. The				
	incident and all actions taken must be promptly recorded in the recipient's notes and the				
	relevant National Incident Management Report Form completed, available at:				
	https://www.hse.ie/eng/about/who/nqpsd/qps-incident-management/nims/nirf-01-v12-				
	person-interactive.pdf				
	<u>person-interactive.pur</u>				
	The child's parent and/or legal guardian must be informed of the incident.				
	Any suspected adverse reactions associated with medicine errors should be reported to				
	the HPRA as outlined below.				
	and the two damined poletic				
	Any errors and near misses not involving medications/not directly involving the vaccine				
	recipient (Needle stick injuries etc.), the incident and all actions taken must be promptly				
	recorded on the relevant National Incident Management Report Form and forwarded to				
	the relevant line manager as per local policy. Refer to https://www.hpsc.ie/a-z/emi/algorithms/EMISharpsAlgo.pdf				
Due se di une fe a non entire a					
Procedure for reporting	The relevant nursing or midwifery staff should report to the HPRA any suspected adverse reactions, in accordance with criteria outlined by the HPRA. This reporting may				
Adverse Drug Reactions to the HPRA	be carried out online at https://www.hpra.ie				
to the fir KA	be carried out offline at https://www.npra.ic				
Resources and equipment	Menjugate (Meningococcal Group C conjugate vaccine)				
required for the	Fridge/cool box with minimum/maximum temperature recording device to				
administration of	monitor the cold chain temperature (between +2°C and +8°C)				
Menjugate	Disposable kidney dishes/coloured trays				
(Meningococcal Group C conjugate vaccine)	Gauze swabs/plasters				
conjugate vaccine)	Sharps bins and bags for disposal of healthcare risk and non-risk waste				
	materials				
	Alcohol hand sanitiser				
	Handwashing facilities				
	Access to telephone				
	Resuscitation equipment and drugs in accordance with the NIAC (2023)				
	Anaphylaxis: Immediate Management in the Community available at:				
	https://www.hiqa.ie/reports-and-publications/niac-immunisation-				
	guideline/anaphylaxis Safa storage areas for medicines and equipment				
	 Safe storage areas for medicines and equipment Current medicine protocol for Meningococcal Group C Conjugate Vaccine 				
	(Menjugate)				
	(,1-9)				

Audit process to identify
appropriate use of the
medicine protocol or
unexpected outcomes

All documentation will be held for review and audit purposes as per local policy.

4.0 Information for vaccine recipient /parent/guardian

Advice to be given to the vaccine recipient/parent/ legal guardian before treatment

For children, Patient Information Leaflet/Fact Sheet must be supplied with the consent form to each parent/legal guardian prior to administration of the vaccine. Reiterate the information provided in the HSE patient information leaflet for the vaccine and translator support if required.

Advice to be given to the vaccine recipient/parent/ legal guardian after treatment

After Treatment

The vaccine recipient must be advised to remain seated in the post vaccination observation area for 15 minutes to allow monitoring of any immediate reaction including possible anaphylactic reaction and must be advised to report any side effects to the registered nurse or registered midwife who is present.

Details of any necessary follow-up, action and referral arrangements

In the event of an adverse reaction the registered nurse or midwife must ensure that all procedures are adhered to as outlined in Section 3.

5.0 Staff authorised to use this medicine protocol

Professional qualifications, training, experience and competence required prior to working under this medicine protocol Registered nurse or registered midwife must have completed all of the following:

- Be a Registered Nurse or Registered Midwife, on the active register maintained by the NMBI
- 2) Primary Childhood Immunisation Programme accessible on www.HSeLanD.ie
- Education programme for nurses and midwives on National Vaccination Education Programme for Registered Nurses/Midwives/Public Health Nurses: 2025/2026 and any updates for nurses and midwives accessible on www.HSeLanD.ie
- 4) An approved *Basic Life Support for Health Care Providers Course* within the last two years (i.e. Irish Heart Foundation (IHF))
- 5) Initial National Anaphylaxis Education Programme for Health Care Professionals accessible on www.HSeLanD.ie followed by a two hour classroom based skills workshop. Recertification is required every two years by completing the on-line National Anaphylaxis Education Programme for Health Care Professionals accessible on www.HSeLanD.ie
- 6) Children having vaccinations and healthcare procedures: Clinical Holding (Professor Lucy Bray/ONMSD, 2023) available at www.HSeLanD.ie

The registered nurse/midwife must complete the Competency Self-Assessment Form to vaccinate Refugees and Applicants Seeking Protection in Ireland available at www.immunisation.ie

References

Glaxosmithkline Vaccines S.r.l. Menjugate (Meningococcal Group C conjugate vaccine) Summary of Product Characteristics and Patient Information Leaflet, available at www.hpra.ie

HSE National Policy on the Management of Sharps and Prevention of Sharp Injuries (2025) available at: https://www2.healthservice.hse.ie/files/191/

National Clinical Guideline No. 30 (2023) – Infection Prevention and Control (IPC) available at: https://www.gov.ie/en/publication/a057e-infection-prevention-and-control-ipc/.

National Immunisation Advisory Committee (2023) *Anaphylaxis: Immediate Management in the Community* available at: https://www.higa.ie/reports-and-publications/niac-immunisation-guideline/anaphylaxis

National Immunisation Advisory Committee *Immunisation Guidelines for Ireland* available at: https://www.hiqa.ie/areas-we-work/national-immunisation-advisory-committee/immunisation-guidelines-ireland

National Immunisation Office (2025/2026) *Supporting Information for Staff: Schools Immunisation Programme* available at: https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/supportingdoc-2025.pdf

National Immunisation Office (2025) Children Who Have Come To Ireland From Another Country: Information For Healthcare Professionals On Catch-Up Vaccination available at https://www.hse.ie/eng/health/immunisation/hcpinfo/botpipa/hcwcatchupothercountries.pdf

National Immunisation Office (2025) *Supporting Information for Vaccinations in General Practice* available at: https://www.hse.ie/eng/health/immunisation/infomaterials/gpsupportingdocpci.pdf

Nursing and Midwifery Board of Ireland (2025) Code of Professional Conduct and Ethics for Register Nurses and Registered Midwives incorporating the Scope of Practice and Professional Guidance. Dublin: Nursing and Midwifery Board of Ireland available at: https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Code-of-Professional-Conduct-and-Ethics.pdf?ext=.pdf

Nursing and Midwifery Board of Ireland (2020) *Guidance for Registered Nurses and Registered Midwives on Medication Administration*. Dublin: Nursing and Midwifery Board of Ireland available at: https://www.nmbi.ie/NMBI/media/NMBI/NMBI-Medication-Administration-2020

Nursing and Midwifery Board of Ireland (2022) *Practice Standards for Midwives* Dublin: Nursing and Midwifery Board of Ireland available at: https://www.nmbi.ie/Standards-Guidance/Midwives-Standards